FILTER
FILTERED INTERVIEW RESULTS
Gilles Labbé
PRESIDENT & CEO, HÉROUX-DEVTEK
Héroux-Devtek continues to grow its landing gear business with its contract for Boeing’s 777.
Martin Staples
DIRECTOR, AMC CONSULTANTS
AMC Consultants describe how the company managed the downturn and some of its implications for Western Australian mining.
Walter Coles
PRESIDENT & CEO, SKEENA RESOURCES LIMITED
Skeena Resources has built up an interesting portfolio of mines based around the Golden Triangle.
Stephen C. Veldhuis
DIRECTOR, MCMASTER MANUFACTURING RESEARCH INSTITUTE, MCMASTER UNIVERSITY
The MMRI collaborates with the Aerospace industry to both develop its students as well as aerospace technologies.
Robert Wills
PRESIDENT, AIRSTART
Airstart has enjoyed continuous growth as it extends its inventory so as to keep aircraft from being grounded anywhere around the world.
Rudi P. Fronk
CHAIRMAN AND CEO, SEABRIDGE GOLD
Seabridge advances at KSM - the largest undeveloped gold project in the world measured by reserves.
Ryan Bignucolo
VICE PRESIDENT OF BUSINESS DEVELOPMENT, MARGAUX RESOURCES LIMITED
Margaux Resources continues to acquire properties around its Jersey-Emerald project in southern British Columbia.
Robert Evans
CFO AND DIRECTOR, ASCOT RESOURCES
Having continued to develop its Premier/Dilworth property during the downturn and boosted by a major recent investment, Ascot Resources are embarking on a massive drilling program.
Jason Neal
GLOBAL CO-HEAD OF MINING AND METALS GROUP, BMO CAPITAL MARKETS
Jason Neal of BMO Capital Markets explains how mining financing trends have evolved over the last couple of years and what he expects going forward.
Romain Trapp
PRESIDENT AND CEO, AIRBUS HELICOPTERS CANADA
Fort Erie in Ontario is an important and expanding hub for Airbus Helicopters and Canada is a top market.
MACIG
SPANISH
SUBSCRIBE TO OUR NEWSLETTER
RECENT PUBLICATIONS
United States Life Sciences 2025 - Digital Interactive
Resilience amid uncertainty. These words encapsulate the US life sciences sector as it navigates 2025. While the industry has largely rebounded from the recent biotech bear market, with clinical trial starts and funding showing signs of rebound, headwinds remain.
Resilience amid uncertainty. These words encapsulate the US life sciences sector as it navigates 2025. While the industry has largely rebounded from the recent biotech bear market, with clinical trial starts and funding showing signs of rebound, headwinds remain.
PARTNER EVENTS
SUBSCRIBE TO OUR
NEWSLETTER
- Get GBR content delivered to your inbox
- Receive industry based news
- Completely free, e-mail only
